Section Arrow
BIVI.NASDAQ
- BioVie Inc
Quotes are at least 15-min delayed:2025/07/20 17:00 EDT
Regular Hours
Last
 8.995
+0.945 (+11.74%)
Day High 
9.09 
Prev. Close
8.05 
1-M High
11.1 
Volume 
56.58K 
Bid
8.51
Ask
9
Day Low
8.15 
Open
8.15 
1-M Low
6.5371 
Market Cap 
14.95M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 7.79 
20-SMA 8.94 
50-SMA 10.09 
52-W High 75 
52-W Low 6.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.30/-15.10
Enterprise Value
15.30M
Balance Sheet
Book Value Per Share
11.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 17:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.